Direct answer
USChinaHealthcare.com explains U.S. and Chinese healthcare systems for readers who need more than headlines or market-size claims. The site focuses on institutions, incentives, regulation, payment, hospitals, life sciences, medtech, digital health, public health, and cross-border strategy.
Why the site exists
U.S.-China healthcare is easy to discuss badly. The same words often mean different things in the two systems: insurance, hospital, approval, reimbursement, procurement, primary care, public health, and market access. A Chinese basic-insurance rule does not work like a U.S. commercial payer policy. FDA clearance does not work like NMPA registration. Public hospitals in China do not play the same role as U.S. hospital systems. A reference site is useful when it slows down those comparisons and names the actual institution involved.
The site also separates current reference content from the preserved legacy conference material. The archive remains available as a historical record. The main site is organized as a living reference library: system overviews, China system pages, U.S. system pages, comparison pages, regulatory and reimbursement pages, market-entry guidance, glossaries, timelines, and topic indices.
Scope
The library covers health-system architecture, public and private hospitals, insurance and reimbursement, public health, primary care, rural and urban healthcare, biopharma, medtech, digital health, AI, data governance, procurement, pricing, clinical trials, FDA and NMPA pathways, U.S. market entry for Chinese companies, China market entry for U.S. companies, and U.S.-China comparison. It favors durable institutional explanation over daily commentary.
That scope is intentionally practical. A reader comparing health insurance should understand why China's basic medical insurance system is often described as covering more than 95 percent of the population, while U.S. insurance analysis has to account for Medicare, Medicaid, employer coverage, ACA marketplaces, and the uninsured. A reader studying market entry should know why CMS separates coding, coverage, and payment, and why China market access can hinge on hospital tier, tendering, volume-based procurement, and local reimbursement rules.
Editorial approach
The site uses official agencies for legal and policy claims, payers for payment claims, regulators for approval claims, international organizations and peer-reviewed literature for public-health and system evidence, and primary source material wherever possible. It avoids unsupported claims that disease burden automatically creates market opportunity. It also avoids pretending that national policy is the same as local implementation.
The practical test is whether a page helps a reader make a sharper judgment. A good article should identify the relevant agency or payer, explain the mechanism, show why the issue matters to patients or companies, and flag the point where a reader should check the underlying rule before acting.
How to use the site
Start with the system hubs if the question is broad. Use the glossary when terminology is unclear. Use the search page when looking for a specific agency, payment rule, disease area, hospital type, or market-entry issue. Use the archive when you need the original conference-era content. For commercial or policy decisions, follow the page links to the underlying source families before relying on a claim.
Reference anchors
- WHO China health financing illustrates the kind of source used for China insurance and financing claims.
- CMS guidance for medical technology companies illustrates U.S. coding, coverage, and payment distinctions.
- FDA Device Advice illustrates the kind of primary source used for U.S. device regulatory pathways.